Andy Lewis in Drug Development & Delivery: Alternative Strategies for Development of Modified-Release Dosage Forms
Andy Lewis, Vice President, Pharmaceutical Sciences, has written an article for Drug Development & Delivery entitled, "Alternative Strategies for Development of Modified-Release Dosage Forms"
Quality Assurance & Compliance: Addressing and Overcoming the Ever-evolving Challenges in Drug Development and Manufacturing
PharmaTech Outlook Interview with Kimberly Paris, SVP & Chief compliance officer at Quotient Sciences: "Addressing and Overcoming the Ever-evolving Challenges in development"
Moving off the critical path: Streamlining strategies for drug substance synthesis and manufacturing
Richard Castledine talks to Pharmaceutical Technology about moving off the critical path and streamlining strategies for drug substance synthesis and manufacturing
Helen Baker Featured in Drug Development & Delivery: "Outsourcing Formulation Development & Manufacturing" Article
Helen Baker, Director, Pharmaceutical Sciences at Quotient Sciences has recently been featured in Drug Development & Delivery's Special Feature: "Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product"
Pharma's Almanac - Mark Egerton - Q: What’s the key to being a leader in the industry?
Mark Egerton, CEO of Quotient Sciences was recently asked to contribute to a piece with Pharma's Almanac, entitled 'What’s the key to being a leader in the industry?'
DCAT Value Chain Insights - CDMO Roundtable: Managing Orphan Drug Projects
Roundtable Interview with Paul Quigley, Principal Research Fellow, Drug Substance,& John McDermott, Executive Drug Development Consultant. Low-volume drugs, such as orphan drugs, present challenges in achieving favorable production economics and in managing the projects themselves. A roundtable of CDMOs provides perspectives on those challenges and best practices to resolve them.